Profile data is unavailable for this security.
About the company
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.
- Revenue in USD (TTM)180.01m
- Net income in USD-121.79m
- Incorporated1993
- Employees486.00
- LocationFibroGen Inc350 BAY STREET, SUITE 100 #6009SAN FRANCISCO 94133United StatesUSA
- Phone+1 (415) 978-1200
- Fax+1 (415) 978-1902
- Websitehttps://www.fibrogen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 36.58m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| Rapt Therapeutics Inc | 0.00 | -107.49m | 36.65m | 70.00 | -- | 0.3837 | -- | -- | -2.78 | -2.78 | 0.00 | 2.74 | 0.00 | -- | -- | 0.00 | -69.76 | -46.30 | -77.90 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| AN2 Therapeutics Inc | 0.00 | -60.70m | 36.75m | 41.00 | -- | 0.419 | -- | -- | -2.04 | -2.04 | 0.00 | 2.94 | 0.00 | -- | -- | 0.00 | -48.27 | -- | -53.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Intensity Therapeutics Inc | 0.00 | -16.26m | 37.18m | 5.00 | -- | 13.47 | -- | -- | -1.18 | -1.18 | 0.00 | 0.2005 | 0.00 | -- | -- | 0.00 | -147.61 | -- | -171.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| OS Therapies Inc | 0.00 | -7.42m | 37.23m | 4.00 | -- | -- | -- | -- | -0.3566 | -0.3566 | 0.00 | -0.0334 | 0.00 | -- | -- | 0.00 | -559.23 | -- | -- | -- | -- | -- | -- | -- | -- | -2.13 | -- | -- | -- | -- | -24.09 | -- | -- | -- |
| Lumos Pharma Inc | 2.21m | -34.92m | 37.45m | 30.00 | -- | 7.62 | -- | 16.98 | -4.29 | -4.29 | 0.2705 | 0.5682 | 0.0676 | -- | 12.75 | 66,818.18 | -107.08 | -29.78 | -132.78 | -32.32 | -- | -- | -1,583.49 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| Calidi Biotherapeutics Inc | 0.00 | -27.95m | 37.66m | 41.00 | -- | -- | -- | -- | -5.61 | -5.61 | 0.00 | -1.10 | 0.00 | -- | -- | 0.00 | -208.29 | -- | -2,279.15 | -- | -- | -- | -- | -- | -- | -28.13 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
| FibroGen Inc | 180.01m | -121.79m | 38.88m | 486.00 | -- | -- | -- | 0.216 | -1.23 | -1.23 | 1.81 | -2.42 | 0.4967 | 1.29 | 7.49 | 370,399.20 | -34.51 | -30.62 | -103.81 | -42.31 | 76.87 | 93.52 | -69.48 | -119.08 | 1.16 | -7.70 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -7.92m | 38.90m | 2.00 | -- | 20.49 | -- | -- | -0.306 | -0.306 | 0.00 | 0.0732 | 0.00 | -- | -- | 0.00 | -137.58 | -- | -154.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 30.09 | -- | -- | -- |
| LAVA Therapeutics NV | 7.40m | -24.18m | 38.91m | 37.00 | -- | 0.9077 | -- | 5.26 | -0.8976 | -0.8976 | 0.2741 | 1.63 | 0.0689 | -- | 3.23 | 199,946.00 | -22.51 | -- | -27.11 | -- | 97.78 | -- | -326.89 | -- | -- | -- | 0.1257 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| Iterum Therapeutics PLC | 0.00 | -30.55m | 40.19m | 14.00 | -- | -- | -- | -- | -2.00 | -2.00 | 0.00 | -0.5068 | 0.00 | -- | -- | 0.00 | -109.80 | -118.12 | -297.32 | -199.23 | -- | -- | -- | -890,554.10 | -- | -7.38 | 2.05 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| Xilio Therapeutics Inc | 4.62m | -62.80m | 40.44m | 73.00 | -- | 1.93 | -- | 8.75 | -1.72 | -1.72 | 0.1046 | 0.4771 | 0.0606 | -- | -- | 63,287.67 | -82.36 | -- | -128.76 | -- | -- | -- | -1,359.37 | -- | -- | -320.73 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
| Rallybio Corp | 598.00k | -66.97m | 41.01m | 25.00 | -- | 0.5792 | -- | 68.59 | -1.59 | -1.59 | 0.0141 | 1.71 | 0.0056 | -- | -- | 13,906.98 | -63.12 | -- | -68.83 | -- | -- | -- | -11,199.50 | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -33.38m | 41.47m | 15.00 | -- | -- | -- | -- | -1.12 | -1.12 | 0.00 | -0.2985 | 0.00 | -- | -- | 0.00 | -512.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to FibroGen Inc's reporting currency: US Dollar USD
37.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| PRIMECAP Management Co.as of 30 Sep 2024 | 9.91m | 9.87% |
| Armistice Capital LLCas of 30 Sep 2024 | 6.80m | 6.77% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 5.85m | 5.82% |
| Acadian Asset Management LLCas of 30 Sep 2024 | 3.91m | 3.89% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 2.35m | 2.34% |
| 683 Capital Management LLCas of 30 Sep 2024 | 2.14m | 2.13% |
| Jacobs Levy Equity Management, Inc.as of 30 Sep 2024 | 2.11m | 2.10% |
| JPMorgan Securities LLC (Investment Management)as of 30 Sep 2024 | 1.67m | 1.67% |
| Marshall Wace LLPas of 30 Sep 2024 | 1.44m | 1.44% |
| GSA Capital Partners LLPas of 30 Sep 2024 | 1.10m | 1.09% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
